Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors

ConclusionIn contrast to prior results in a pediatric population, adult patients did not tolerate alisertib combined with irinotecan at clinically meaningful doses due to hematologic and gastrointestinal toxicities. The study was registered with ClinicalTrials.gov under study number NCT01923337 on Aug 15, 2013.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research